Placenta-mediated pregnancy complications in women with a history of late fetal loss and placental infarction without thrombophilia: risk of recurrence and efficacy of pharmacological prophylactic interventions. A 10-year retrospective study

References

• Giannubilo SR, Landi B, Ciavattini A. Preeclampsia: What could happen in a subsequent pregnancy? Obstet Gynecol Surv. 2014;69(12):747–762.
   PubMed Web of Science ®Google Scholar
• Reijnders IF, Mulders A, Koster MPH. Placental development and function in women with a history of placenta-related complications: a systematic review. Acta Obstet Gynecol Scand. 2018;97(3):248–257.
   PubMed Web of Science ®Google Scholar
• Malacova E, Regan A, Nassar N, et al. Risk of stillbirth, preterm delivery, and fetal growth restriction following exposure in a previous birth: systematic review and meta-analysis. BJOG. 2018;125(2):183–192.
   PubMed Web of Science ®Google Scholar
• Wainstock T, Sheiner E. Clinical factors associated with preeclampsia recurrence. Pregnancy Hypertens. 2022;30:31–35.
   PubMed Web of Science ®Google Scholar
• von Elm E, Altman DG, Egger M, et al. STROBE initiative strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med. 2007;4(10):e296.
   PubMed Web of Science ®Google Scholar
• Bertino E, Spada E, Occhi L, et al. Neonatal anthropometric charts: the Italian neonatal study compared with other European studies. J Pediatr Gastroenterol Nutr. 2010;51(3):353–361.
   PubMed Web of Science ®Google Scholar
• Hypertension in pregnancy: diagnosis and management. NICE guideline, 25 June. 2019.
   Google Scholar
• Franco C, Walker M, Robertson J, et al. Placental infarction and thrombophilia. Obstet Gynecol. 2011;117(4):929–934.
   PubMed Web of Science ®Google Scholar
• Wallenburg HC. Prevention of pre-eclampsia: status and perspectives 2000. Eur J Obstet Gynecol Reprod Biol. 2001;94(1):13–22.
   PubMed Web of Science ®Google Scholar
• Askie LM, Duley L, Henderson-Smart DJ, et al. Antiplatelet agents for prevention of preeclampsia: a meta-analysis of individual patient data. Lancet. 2007;369(9575):1791–1798.
   PubMed Web of Science ®Google Scholar
• Henderson JT, Whitlock EP, O’Connor E, et al. Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. preventive services task force. Ann Intern Med. 2014;160(10):695–703.
   PubMed Web of Science ®Google Scholar
• Kingdom JCP, Drewlo S. Is heparin a placental anticoagulant in high-risk pregnancies? Blood. 2011;118(18):4780–4788.
   PubMed Web of Science ®Google Scholar
• Dutta S, Kumar S, Hyett J, et al. Molecular targets of aspirin and prevention of preeclampsia and their potential association with circulating extracellular vesicles during pregnancy. Int J Mol Sci. 2019;20(18):4370.
   PubMed Web of Science ®Google Scholar
• Girardi G, Redecha P, Salmon JE. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med. 2004;10(11):1222–1226.
   PubMed Web of Science ®Google Scholar
• Lynch AM, Murphy JR, Gibbs RS, et al. The interrelationship of complement-activation fragments and angiogenesis-related factors in early pregnancy and their association with pre-eclampsia. BJOG. 2010;117(4):456–462.
   PubMed Web of Science ®Google Scholar
• Duffett L, Rodger MA. LMWH to prevent placenta-mediated pregnancy complications: an update. Br J Haematol. 2015;168(5):619–638.
   PubMed Web of Science ®Google Scholar
• Rodger MA, Carrier M, Le Gal G, et al. Meta-analysis of low-molecular-weight heparin to prevent recurrent placenta-mediated pregnancy complications. Blood. 2014;123(6):822–828.
   PubMed Web of Science ®Google Scholar
• Roberge S, Demers S, Nicolaides KH, et al. Prevention of pre-eclampsia by low-molecular-weight heparin in addition to aspirin: a meta-analysis. Ultrasound Obstet Gynecol. 2016;47(5):548–553.
   PubMed Web of Science ®Google Scholar
• Groom KM, David AL. The role of aspirin, heparin, and other interventions in the prevention and treatment of fetal growth restriction. Am J Obstet Gynecol. 2018;218(2S):S829–S840.
   PubMed Web of Science ®Google Scholar
• Skeith L. Low-molecular-weight heparin for the prevention and treatment of placenta-mediated pregnancy complications: the tides have shifted. Thromb Res. 2018;170:207–208.
   PubMed Web of Science ®Google Scholar
• Chang L, Liu Y, Zhang X, et al. The clinical effect of aspirin combined with low-molecular-weight heparin in the treatment of severe preeclampsia and the combination’s effect on pregnancy outcomes. Am J Transl Res. 2021;13(8):9113–9121.
   PubMed Web of Science ®Google Scholar
• Rey E, Garneau P, David M, et al. Dalteparin for the prevention of recurrence of placental mediated complications of pregnancy in women without thrombophilia: a pilot randomized controlled trial. J Thromb Haemost. 2009;7(1):58–64.
   PubMed Web of Science ®Google Scholar
• Rodger MA, Hague WM, Kingdom J, et al. Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial. Lancet. 2014;384(9955):1673–1683.
   PubMed Web of Science ®Google Scholar